Alpha Paradigm Partners, LLC Halozyme Therapeutics, Inc. Transaction History
Alpha Paradigm Partners, LLC
- $239 Million
- Q4 2022
A detailed history of Alpha Paradigm Partners, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Alpha Paradigm Partners, LLC holds 6,357 shares of HALO stock, worth $363,683. This represents 0.15% of its overall portfolio holdings.
Number of Shares
6,357
Previous 23,099
72.48%
Holding current value
$363,683
Previous $913,000
60.46%
% of portfolio
0.15%
Previous 0.4%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
488Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.01 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$737 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$333 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$231 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$213 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.97B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...